NMN and NR both boost NAD+ levels, but they differ in bioavailability, cost, and clinical evidence. Here is what the research says about choosing between them.
NAD+ (nicotinamide adenine dinucleotide) has become one of the most discussed molecules in longevity science. This coenzyme participates in hundreds of metabolic reactions, powers the sirtuins that protect our DNA, and fuels the PARP enzymes that repair it. The problem is that NAD+ levels decline roughly 50% between age 20 and 60, and this decline appears to accelerate many hallmarks of aging. Enter NMN and NR — two NAD+ precursors that have attracted enormous interest, significant investment, and a heated debate about which one actually works better.
Your body cannot simply absorb NAD+ from a supplement — the molecule is too large to enter cells directly. Instead, it must be built from precursor compounds that cross cell membranes and are then converted internally. Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are biosynthetic intermediates on the pathway to NAD+. Think of them as different entry points into the same production line.
NAD+ is the fuel for several longevity-associated enzymes. Sirtuins (SIRT1-SIRT7) are NAD+-dependent deacylases that regulate gene expression, mitochondrial function, inflammation, and stress resistance. Declining NAD+ impairs sirtuin activity, which David Sinclair of Harvard Medical School has argued is a central mechanism of aging. Additionally, PARP1, the enzyme that rushes to repair DNA strand breaks, consumes enormous amounts of NAD+ — especially under conditions of oxidative stress. When NAD+ is scarce, DNA repair is compromised.
NMN is one step closer to NAD+ in the biosynthetic pathway than NR is. It is converted to NAD+ by the enzyme NMNAT (nicotinamide mononucleotide adenylyltransferase). NMN naturally occurs in small amounts in foods like edamame, broccoli, avocado, and cucumber, but food sources alone are far too low to meaningfully raise NAD+ levels.
The animal data for NMN is impressive. Studies in aging mice have shown that NMN supplementation improves energy metabolism, enhances muscle function, prevents age-related weight gain, and improves insulin sensitivity. A notable 2016 study in Cell Metabolism by Yoshino and colleagues demonstrated that NMN supplementation reversed several aspects of physiological decline in aged mice. However, the classic caveat applies: mice are not humans.
Human clinical trials for NMN have accelerated since 2020. A randomised, placebo-controlled trial published in Science in 2021 (Yoshino et al.) found that 250 mg/day of NMN for 10 weeks significantly raised muscle NAD+ levels and improved insulin signalling in postmenopausal women with prediabetes. A 2022 study in NPJ Aging found that 300 mg/day increased NAD+ levels in older adults and correlated with improved gait speed. A 2023 trial in GeroScience found that 900 mg/day was safe and further increased NAD+ metabolites.
If you are looking to try NMN, reputable options include Tru Niagen NMN and Renue by Science Pure NMN, which offer third-party tested formulations.
NR (nicotinamide riboside) has a longer clinical research record than NMN, largely because of its earlier commercial introduction through Chromadex, the company that brought Tru Niagen to market. NR is converted to NMN inside cells before becoming NAD+, meaning it is one step further back in the pathway.
The human evidence for NR is solid. A 2016 pilot study in Nature Communications by Martens and colleagues showed that 1,000 mg/day of NR for six weeks significantly raised blood NAD+ levels in healthy middle-aged adults with no serious adverse effects. A 2018 clinical trial in Nature Communications (Dollerup et al.) found that NR supplementation raised NAD+ levels but did not significantly affect insulin sensitivity in obese men. A 2020 trial in Cell Reports Medicine found that NR raised NAD+ in skeletal muscle of older adults and modestly reduced blood pressure.
Good NR supplement choices include Tru Niagen (the most clinically studied NR brand) and Elysium Basis, which combines NR with pterostilbene as a SIRT1 activator.
The bioavailability debate is central to the NMN vs NR question. Early pharmacokinetic studies suggested that orally consumed NMN might be degraded in the gut to nicotinamide before being absorbed — essentially bypassing the NAD+ pathway and entering through a less efficient route. This led some researchers to question whether standard oral NMN was reaching target tissues.
However, a 2022 paper by Liao and colleagues in Nature Aging provided important clarification: oral NMN is indeed absorbed intact in humans, at least in part via a specific small intestinal transporter called Slc12a8. This discovery resolved much of the controversy. Sublingual NMN formulations — where the powder dissolves under the tongue — bypass gut degradation entirely and may offer higher bioavailability, which is why products like ProHealth Longevity NMN sublingual powder have gained a following among biohackers.
NR appears to have reasonably reliable oral bioavailability, with multiple studies confirming that oral dosing raises circulating NAD+ metabolites.
Based on current human trials:
Both compounds appear safe at these doses. The main reported side effects are mild: occasional GI discomfort, flushing (more common with higher doses), and transient fatigue during initial supplementation.
At doses where meaningful NAD+ elevation has been demonstrated:
NMN prices have dropped significantly as the market has grown. Generic NMN powder from reputable suppliers like Bulk Supplements NMN can significantly reduce costs.
David Sinclair favours NMN and has been open about taking it himself. He argues that NMN's closer proximity to NAD+ in the biosynthetic pathway gives it a theoretical advantage. Charles Brenner, the biochemist who discovered NR and has financial ties to Chromadex, predictably argues for NR. Both researchers have credibility and both have conflicts of interest.
Peter Attia has been more circumspect, noting that the clinical evidence for either compound meaningfully extending human healthspan is still limited.
The honest answer is that the clinical evidence does not yet definitively prove one is superior to the other for human longevity. Both raise NAD+ levels. Both appear safe. The practical considerations that should guide your choice:
1. Budget: NR from Tru Niagen is slightly cheaper; generic NMN powder is cheapest
2. Evidence recency: NMN has more recent, better-powered human trials
3. Delivery preference: If absorption concerns you, sublingual NMN may have an edge
The most important context is that NAD+ supplementation should be viewed as one component of a comprehensive longevity strategy, not a magic bullet. Combining NMN or NR with regular exercise, a low-calorie-density diet, and other evidence-based interventions will always be more powerful than any single supplement alone.